Inhibitors of adenosine deaminase

https://doi.org/10.1016/0163-7258(82)90023-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (174)

  • D.C. Baker et al.

    Identification of the bioactive enantiomer of erythro-3-(adenin-9-yl)-2-nonanol (EHNA). A semitight binding inhibitor of adenosine deaminase

    Biochem. Pharmac.

    (1981)
  • R.L. Blakley

    The biosynthesis of thymidylic acid IV. Further studies on thymidylate synthetase

    J. biol. Chem.

    (1963)
  • J.H. Burchenal et al.

    Studies of 6-N-hydroxylamino-9-β-d-ribofuranosyl purine in mouse leukemia

    Biochem. Pharmac.

    (1967)
  • C.E. Cass et al.

    Inhibition by nitrobenzylthioinosine of uptake of adenosine. 2′-deoxyadenosine and 9-β-d-arabinofuranosyladenine by human and mouse erythrocytes

    Biochem. Pharmac.

    (1975)
  • C.E. Cass et al.

    Nitrobenzylthioinosine binding sites in the erythrocyte membrane

    Biochim. biophys. Acta

    (1976)
  • S. Cha

    Tight binding inhibitors: I. Kinetic behavior

    Biochem. Pharmac.

    (1975)
  • S. Cha

    Tight-binding inhibitors: III. A new approach for the determination of competition between tight-binding inhibitors and substrates—inhibition of adenosine deaminase by coformycin

    Biochem. Pharmac.

    (1976)
  • S. Cha et al.

    Tight-binding inhibitors: II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin

    Biochem. Pharmac.

    (1975)
  • M.M. Chassin et al.

    Enzyme inhibition titration assay for 2′-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats

    Biochem. Pharmac.

    (1979)
  • A. Coddington et al.

    The formation of deoxyadenosine phosphate in ascites tumor cells in vitro and its effect on deoxyribonucleic acid synthesis

    Biochim. biophys. Acta

    (1963)
  • J. Constine et al.

    Adenosine deaminase inhibitors: Differential effects on multiple forms of adenosine deaminase

    Biochem. biophys. Res. Commun.

    (1978)
  • P.E. Daddona et al.

    Human adenosine deaminase: Purification and subunit structure

    J. biol. Chem.

    (1977)
  • C. Frieden et al.

    Adenylate deaminase: Potent inhibition by 2′-deoxycoformycin 5′-phosphate

    Biochem. biophys. Res. Commun.

    (1979)
  • E.R. Giblett et al.

    Adenosine deaminase deficiency in two patients with severely impaired cellular immunity

    Lancet

    (1972)
  • R.I. Glazer

    The effects of 2′-deoxycoformycin on the action of cordycepin on nuclear RNA synthesis in regenerating liver

    Toxicol. appl. Pharmac.

    (1978)
  • R.I. Glazer et al.

    Cordycepin and xylosyladenine: Inhibitors of methylation of nuclear RNA

    Biochem. biophys. Res. Commun.

    (1978)
  • R.I. Glazer et al.

    Evidence that xylosyladenine affects methylation by inhibition of S-adenosyl-l-methionine synthesis

    Cancer Lett.

    (1979)
  • K.R. Harrap et al.

    Adenosine metabolism in cultured lymphoid cells

    Adv. Enzyme Regul.

    (1977)
  • J.F. Henderson et al.

    Specificity of adenosine deaminase inhibitors

    Biochem. Pharmac.

    (1977)
  • D.G. Johns et al.

    Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin

    Biochem. Pharmac.

    (1976)
  • R.G. Keightley et al.

    Successful fetal liver transplantation in a child with severe combined immunodeficiency

    Lancet

    (1975)
  • C.T. Lum et al.

    Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA)

    Clin. Immunol. Immunopath.

    (1978)
  • P.P. Major et al.

    Clinical pharmacology of deoxycoformycin

    Blood

    (1981)
  • W.W. Ackermann et al.

    Enzyme inhibition in relation to chemotherapy

  • R.H. Adamson et al.

    Some aspects of the pharmacology of the adenosine deaminase inhibitors 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine

  • R.H. Adamson et al.

    Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin

    Pharmacology

    (1977)
  • R.P. Agarwal

    Recovery of 2′-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo

    Cancer Res.

    (1979)
  • R.P. Agarwal

    Recovery of deoxycoformycin (DCF) inhibited adenosine deaminase (ADA) of mouse tissues

    Pharmacologist

    (1980)
  • R.P. Agarwal

    Deoxycoformycin toxicity in mice after long term treatment

    Cancer Chemother. Pharmac.

    (1980)
  • R.P. Agarwal et al.

    Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency

    J. clin. Invest.

    (1976)
  • R.P. Agarwal et al.

    Role of the cell membrane in the interaction of adenosine deaminase and deoxycoformycin

  • J.R.S. Arch et al.

    The control of the metabolism and the hormonal role of adenosine

    Essays Biochem.

    (1978)
  • H.P. Baer et al.

    On the mechanism of adenosine deaminase action

    Biochem. biophys. Res. Commun.

    (1966)
  • H.P. Baer et al.

    Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides

    (1979)
  • J.J. Ballet et al.

    Inhibition of maturation of human percursor lymphocytes by coformycin, inhibitor of the enzyme adenosine deaminase

    J. exp. Med.

    (1976)
  • G. Bastian et al.

    Adenosine deaminase inhibitors. The conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenine

    J. med. Chem.

    (1981)
  • R.S. Benjamin et al.

    Phase I and biochemical pharmacological studies of deoxycoformycin

  • M.D. Bessodes et al.

    Effect of chirality in erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) on adenosine deaminase inhibition

    Biochem. Pharmac.

    (1981)
  • P.E. Borondy et al.

    Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine)

    Ann. N.Y. Acad. Sci.

    (1977)
  • J.J. Brink et al.

    Metabolic effects of 9-β-d-arabinosyladenines in ascites tumor cells

    Cancer Res.

    (1964)
  • Cited by (104)

    • Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2′s-hydroxy-3′s-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors

      2017, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      The desired analogues were synthesized using intermediate 5a and 5b as described in Scheme 6. In two steps 3-hydroxy group of 5a/5b was converted to mesylate and displacement by SN2 reaction with 4-imidazolecarboxamide in the presence of NaH in DMF afforded 25a-b.28 Whereas 25c-f were synthesized by reacting 4-Diboc-aminopyrazolo[3,4-d]pyrimidine25a/4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 5a/5b under Mitsunobu condition, Finally deprotection of 25a-f afforded desired compounds 26a-f. We probed the role of C-2′ hydroxyl and chirality on potency (P3 segment modification, Fig. 2) by converting secondary hydroxyl of 7b to ketone 29 and tertiary hydroxyl group 31.

    • Dose finding of 3'deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose

      2015, Microbial Pathogenesis
      Citation Excerpt :

      Mechanistically, as an adenosine analogue, Cordycepin most likely replaces the ribose of adenosine and consequently interrupts nucleolar RNA synthesis [15–17]. On the other hand, Pentostatin is a deoxyadenosine analogue and a potent inhibitor of E-ADA, an enzyme of purine metabolism [18]. Blockade of E-ADA leads to the accumulation of cytotoxic de-oxyadenosine triphosphate metabolites in the cell, inhibition of DNA synthesis and eventual cell death [19,20].

    • Functional nucleic acid entrapment in sol-gel derived materials

      2013, Methods
      Citation Excerpt :

      Each final material, single-phase or top layer, is allowed to gel and age for 2 h prior to addition of the buffer overlay. Assays are performed by first adding 15 different concentrations of EHNA (one per well), spanning the expected IC50 value of 100 nM (derived from literature KI of 6.5 nM [51]), to the buffer overlay and incubating for 60 min. Following inhibitor incubation, 1 mM final concentration of adenosine is added and the fluorescence monitored over time as in experiments listed above.

    View all citing articles on Scopus
    View full text